BIO-RAD LABORATORIES, INC.(BIO)— Stock Profile, AI Score & Financials

Technology · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BIO-RAD LABORATORIES, INC. (BIO) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores BIO at 48.9/100 on a 32-signal composite quality model, placing it at rank #1,689 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (13.4) and revenue growth (26.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIO-RAD LABORATORIES, INC. reports quarterly revenue of $651.0M, net income of $371.4M, free cash flow of $66.7M. Top institutional holders of BIO by reported 13-F value include First Eagle Investment Management, BlackRock, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BIO trades on the NYSE exchange and files with the SEC under CIK 12208. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-RAD LABORATORIES, INC. directly from SEC EDGAR.